skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8799

Neurotransmitter testing of the urine: a comprehensive analysis

Original Research

(4902) Views  (762) Full article downloads

Authors: Marty Hinz, Alvin Stein, George Trachte, et al

Published Date October 2010 Volume 2010:2 Pages 177 - 183
DOI: http://dx.doi.org/10.2147/RRU.S13370

Marty Hinz1, Alvin Stein2, George Trachte3, Thomas Uncini4
1Clinical Research, NeuroResearch Clinics, Inc., Cape Coral, FL, USA; 2Stein Orthopedic Associates, Plantation, FL, USA; 3Department of Physiology and Pharmacology, University of Minnesota Medical School, MN, USA; 4DBS Labs, Duluth, MI, USA

Abstract: This paper analyzes the statistical correlation of urinary serotonin and dopamine data in subjects not suffering from monoamine-secreting tumors such as pheochromocytoma or carcinoid syndrome. Peer-reviewed literature and statistical analyses were searched and monoamine (serotonin and dopamine) assays defined in order to facilitate their proper interpretation. Many research findings in the literature are novel. Baseline assays completed with no monoamine precursors differ from baseline assays performed on a different day in the same subject. There is currently no scientific basis, value, or predictability in obtaining baseline monoamine assays. Urinary assays performed while taking precursors can demonstrate a lack of correlation or unexpected correlations such as inverse relationships. The only valid model for interpretation of urinary monoamine assays is the “three-phase model” which leads to predictability between monoamine assays and precursor administration in varied amounts.
Purpose: This paper reviews the basic science of urinary monoamine assays. Results of statistical analysis correlating baseline and nonbaseline assays are reported and provide valid methods for interpretation of urinary serotonin and dopamine results.
Patients and methods: Key scientific claims promoting the validity of the urinary neurotransmitter testing (UNT) model applications are discussed. Many of these claims were not supported by the scientific literature. Matched-pairs t-tests were performed on several groupings. Results of all statistical tests were compared with peer-reviewed literature.
Results: The statistical analysis failed to support the UNT model. Peer-reviewed literature search failed to verify scientific clams made in support of applications of the UNT model in many cases.

Keywords: serotonin, dopamine, urinary neurotransmitter testing




 

Other articles by Dr Marty Hinz

A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
Amino acid management of Parkinson’s disease: a case study
Amino acid-responsive Crohn's disease: a case study
APRESS: apical regulatory super system, serotonin, and dopamine interaction
Monoamine depletion by reuptake inhibitors
Relative nutritional deficiencies associated with centrally acting monoamines
The discrediting of the monoamine hypothesis
The dual-gate lumen model of renal monoamine transport
Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation
Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine
Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model”


Readers of this article also read:

Both stimulatory and inhibitory effects of dietary 5-hydroxytryptophan and tyrosine are found on urinary excretion of serotonin and dopamine in a large human population
The dual-gate lumen model of renal monoamine transport
A pilot study differentiating recurrent major depression from bipolar disorder cycling on the depressive pole
Amino acid-responsive Crohn's disease: a case study
Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation
Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine
Amino acid management of Parkinson’s disease: a case study
Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model”
APRESS: apical regulatory super system, serotonin, and dopamine interaction